ibandronic acid

  • Email
  • Help


The marketing authorisation for Destara has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 31/12/2009 .

Authorisation details

Product details

Product details for Destara
Agency product numberEMEA/H/C/000103
Active substance

ibandronic acid

International non-proprietary name (INN) or common name

ibandronic acid

Therapeutic area HypercalcemiaCancer
Anatomical therapeutic chemical (ATC) code M05BA06

Publication details

Publication details for Destara
Marketing-authorisation holder

Roche Registration Ltd.

Date of issue of marketing authorisation valid throughout the European Union25/06/1996

Contact address:

Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
United Kingdom

Product information

Product information

31/12/2009  Destara -EMEA/H/C/000103


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

Treatment of tumour-induced hypercalcaemia with or without metastases.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated

Initial marketing-authorisation documents

Name Language First published Last updated


This medicine is now withdrawn from use in the European Union